ViiV Healthcare is a global specialist HIV company focused on the research, development, and commercialization of antiretroviral therapies and prevention options. Formed in 2009 as a joint venture by GSK and Pfizer, with Shionogi later joining as a shareholder, it is majority-owned by GSK. The company is headquartered in the United Kingdom and operates worldwide across clinical development, manufacturing, and access programs.
Its portfolio includes dolutegravir-based treatments such as Tivicay (dolutegravir), Triumeq (abacavir/dolutegravir/lamivudine), Dovato (dolutegravir/lamivudine), and Juluca (dolutegravir/rilpivirine, in collaboration with Janssen). ViiV Healthcare also develops long-acting cabotegravir regimens for HIV treatment and prevention, including Cabenuva (cabotegravir with rilpivirine, in partnership with Janssen; marketed as Vocabria plus Rekambys in some regions) and Apretude (cabotegravir) for pre-exposure prophylaxis. The company works with public and private partners to expand access to HIV medicines in low- and middle-income countries.
None yet. When a new project in the record names ViiV Healthcare as owner, partner or investor, it shows here.
Long-acting cabotegravir + rilpivirine achieved superior viral suppression versus standard oral ART at six months when initiated in people with detectable HIV.
LATA shows superiority in adolescents; OPERA real‑world suppression comparable to oral regimens; cabotegravir injections rated better than lenacapavir; EXTEND 4M tests 4‑month formulation.
Lotivibart, combined with CAB LA, maintained viral suppression in 94% of participants. Study progresses to test twice-yearly dosing. Well-tolerated with fewer adverse events in IV group.
VH184 and VH499 show promise for twice-yearly HIV treatment, with improved resistance and tolerability, reducing the need for daily medication.
